IRWD
Ironwood Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
IRWD fundamentals
Ironwood Pharmaceuticals (IRWD) released its earnings on Feb 25, 2026: revenue was 47.71M (YoY -47.31%), missed estimates; EPS was -0.01 (YoY -150.00%), beat estimates.
Revenue / YoY
47.71M
-47.31%
EPS / YoY
-0.01
-150.00%
Report date
Feb 25, 2026
IRWD Earnings Call Summary for Q4,2025
- LINZESS Revival: 2026 U.S. net sales expected to exceed $1.1 billion, up 30% YoY, driven by price adjustment and demand growth. 2025 ended with $250M cash, enabling debt reduction to $300M by year-end.
- Apraglutide Milestone: STARS-2 Phase III trial begins Q2 2026, targeting 124 patients with SBS-IF. FDA alignment on endpoints increases confidence in eventual NDA submission by 2029.
- Financial Discipline: 2025 operating expenses reduced by $61M, with 2026 adjusted EBITDA >$300M. Focus on deleveraging to 1x EBITDA while funding clinical trials.
- Market Leadership: LINZESS maintains 45% IBS-C/CC market share, with 5.7M unique patients treated. Apraglutide's once-weekly profile positions it as best-in-class against daily GLP-2 competitors.
EPS
Actual | 0.02 | 0.16 | 0.21 | 0.27 | 0.25 | 2.39 | 0.34 | 0.25 | 0.21 | 0.21 | 0.28 | 0.27 | 0.25 | -6.84 | 0.09 | -0.01 | -0.03 | -0.01 | 0.02 | 0.02 | -0.23 | 0.14 | 0.23 | -0.01 | ||||||||||
Forecast | 0.0462 | 0.088 | 0.1381 | 0.285 | 0.25 | 0.2233 | 0.3067 | 0.28 | 0.315 | 0.3279 | 0.27 | 0.278 | 0.2467 | 0.2467 | 0.204 | 0.2 | 0.202 | 0.1559 | 0.072 | 0.0846 | -0.1362 | 0.0233 | 0.1057 | -0.065 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -56.71% | +81.82% | +52.06% | -5.26% | 0.00% | +970.31% | +10.86% | -10.71% | -33.33% | -35.96% | +3.70% | -2.88% | +1.34% | -2872.60% | -55.88% | -105.00% | -114.85% | -106.41% | -72.22% | -76.36% | -68.87% | +500.86% | +117.60% | +84.62% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.94M | 89.43M | 103.47M | 116.68M | 88.84M | 104.03M | 103.75M | 117.13M | 97.53M | 97.23M | 108.64M | 107.20M | 104.06M | 107.38M | 113.74M | 117.55M | 74.88M | 94.40M | 91.59M | 90.55M | 41.14M | 85.24M | 122.06M | 47.71M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.34M | 84.76M | 93.10M | 111.95M | 91.15M | 93.85M | 105.28M | 110.17M | 96.62M | 103.55M | 109.15M | 108.04M | 100.35M | 103.70M | 114.00M | 117.47M | 105.75M | 107.10M | 91.22M | 93.77M | 45.90M | 60.77M | 74.71M | 50.92M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +0.76% | +5.51% | +11.13% | +4.22% | -2.53% | +10.85% | -1.45% | +6.31% | +0.94% | -6.10% | -0.47% | -0.78% | +3.70% | +3.55% | -0.23% | +0.07% | -29.19% | -11.86% | +0.41% | -3.44% | -10.36% | +40.25% | +63.38% | -6.30% |
Earnings Call
You can ask Aime
What were the key takeaways from Ironwood Pharmaceuticals's earnings call?What is the revenue and EPS growth rate for Ironwood Pharmaceuticals year over year?What is Ironwood Pharmaceuticals's gross profit margin?What does Ironwood Pharmaceuticals do and what are its main business segments?Did Ironwood Pharmaceuticals beat or miss consensus estimates last quarter?What factors drove the changes in Ironwood Pharmaceuticals's revenue and profit?What is the market's earnings forecast for Ironwood Pharmaceuticals next quarter?What were the key takeaways from Ironwood Pharmaceuticals’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
